KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read More
Alberto joined Selexis with nearly 30 years of experience leading the financial operations of numerous international companies, including Unilever and Coty Inc. Specifically, he has managed a wide range of business transformation programs and supported merger and acquisition (M&A) activities, whilst continuously improving the finance and tax compliance frameworks and increasing the efficiency of finance processes through the implementation of information management solutions.
Alberto most recently held the role of president for Evolve Consulting Sàrl in Coppet, Switzerland, which he founded to provide end-to-end solutions in the finance transformation and real estate areas. He signed off on a consulting mandate with Coty Inc. to support the $5 billion P&G Specialty Beauty post-merger integration program in specific finance areas. During the previous 10 years, he held various managerial roles at Coty Inc. As senior vice president of shared services, he was responsible for the global finance shared services organizational design, which resulted from the P&G Specialty Beauty integration. In his prior role of CFO Europe for the company, he managed the finance function in the European region, delivering significant operational savings and helping to develop Coty’s go-to-market strategy across multiple product categories and geographies.
Alberto earned a degree in business administration with majors in banking and financial institutions from the University Luigi Bocconi in Milan, Italy.
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2023 Selexis SA. All Rights Reserved.